The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 5 of the 28 sources its claims cite were checked for support.
Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes
Open accessAbstract
De novo mutations affect risk for many diseases and disorders, especially those with early-onset. An example is autism spectrum disorders (ASD). Four recent whole-exome sequencing (WES) studies of ASD families revealed a handful of novel risk genes, based on independent de novo loss-of-function (LoF) mutations falling in the same gene, and found that de novo LoF mutations occurred at a twofold higher rate than expected by chance. However successful these studies were, they used only a small fraction of the data, excluding other types of de novo mutations and inherited rare variants. Moreover, such analyses cannot readily incorporate data from case-control studies. An important research challenge in gene discovery, therefore, is to develop statistical methods that accommodate a broader class of rare variation. We develop methods that can incorporate WES data regarding de novo mutations, inherited variants present, and variants identified within cases and controls. TADA, for Transmission And De novo Association, integrates these data by a gene-based likelihood model involving parameters for allele frequencies and gene-specific penetrances. Inference is based on a Hierarchical Bayes strategy that borrows information across all genes to infer parameters that would be difficult to estimate for individual genes. In addition to theoretical development we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis. Thus TADA's integration of various kinds of WES data can be a highly effective means of identifying novel risk genes. Indeed, application of TADA to WES data from subjects with ASD and their families, as well as from a study of ASD subjects and controls, revealed several novel and promising ASD candidate genes with strong statistical support.
Overview
CoChat Summary
TL;DR
TADA is a hierarchical Bayesian gene-based method that integrates de novo, inherited transmitted/nontransmitted, and case-control rare variant data to identify disease risk genes. Applied to autism spectrum disorder exome data, it estimates about 1,000 ASD risk genes with average loss-of-function relative risk about 20 and identifies novel candidate genes with greater power than de novo-only or meta-analytic tests.
Key findings
- In simulations, TADA had superior power: for a gene with typical parameter values at type I error 0.001, its power was about fivefold larger than the De Novo and Meta tests; genome-wide at FDR below 10%, TADA identified more than 200 ASD risk genes, versus about 50 for the De Novo test and about 70 for the Meta test.
- Using the model, the authors estimated approximately 1,000 ASD risk genes with an average relative risk of approximately 20 due to LoF mutations; an earlier multi-hit-count analysis gave a plausible range of 550 to 1000 risk genes.
- De novo LoF mutations occurred at about a twofold higher rate in ASD probands than unaffected siblings; de novo probably damaging missense (Mis3) mutations were also higher in probands but less strikingly, while other mutation types showed essentially no difference.
- Applying TADA to combined ASD data, 15 genes met an FDR less than 20%, including all five genes with two de novo LoF mutations and novel candidates such as KATNAL2, CHD8, S100G, DYRK1A, PPM1D, SCN2A, CUL3, DEAF1, BANK1, POGZ, WDR55, FAM91A1, and COL25A1.
Methods
- TADA uses a gene-based likelihood model for rare deleterious mutations acting dominantly, with parameters for mutation rate, allele frequency, and gene-specific relative risk/penetrance; it tests relative risk equal to 1 versus greater than 1 using a Hierarchical Bayes/Empirical Bayes strategy that borrows information across genes and can combine multiple mutation types.
- Data included de novo mutations from 932 ASD families across four whole-exome sequencing studies, transmitted/nontransmitted variants from 641 of those families, and case-control data from the ARRA Autism Sequencing Consortium consisting of 935 ASD subjects and 870 controls; analyses focused on LoF and PolyPhen2 “probably damaging” (Mis3) mutations.
- The authors performed simulations under null and alternative models using estimated ASD genetic parameters, applied TADA to ASD data with Benjamini-Hochberg FDR control, and conducted sensitivity analyses varying mutation rates and the prior average relative risk.
Limitations
- The paper states that genotyping/sequencing errors can bias family and combined data analyses, though it argues the variant calls were carefully validated and harmonized; modeling measurement errors is left for future research. It also notes TADA is a one-sided test powered to detect over-transmitted risk variants, so under-transmission bias is not a major concern.
- The paper cautions that the S100G signal is based on a splice variant common in African populations and should be viewed with caution, and that a C1orf95 signal is likely due to population substructure.
- Evident in the text: the method relies on PolyPhen2 classification and downweighting of missense mutations, and the top-gene list uses an FDR threshold of less than 20%, which is relatively permissive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
4 Valid · 7 Not valid · 19 Not checked · 80 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] (see Text S1).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Introduction states that for these data 'population structure appears to be corrected for by using principal components analysis'. In Results > Distribution of AASC Data the paper defines exactly the modified genomic control factor the citing sentence points to — lambda-1, 'a variant on the GC principle based on the first quantile (rather than the median) of the p-value distribution', which 'has an expected value of 1 when there is no confounding due to population structure (see Text S1)' — and reports that the observed lambda-1 'is close to the mean of the simulated distribution for all 3 choices of eigen-vectors', that it is 'controlled fairly well in the Baylor and Broad samples individually' with only 'a slight inflation (1.08)' in mega SKAT, and that the test statistics 'follow the null hypothesis quite closely'. The residual elevation of the standard median-based GC factor is explicitly attributed to SKAT p-values biased toward .5, 'an apparent, but uninteresting inflation', not to stratification — so the substance of 'negligible overall inflation from population stratification' is stated here, with the paper's own hedge ('slight inflation' in mega-analysis) being the mildest qualification. (LLM, conf=0.82)
- Not checked yetcites [10] B Devlin, 1999, Genomic control for association studies, Biometrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This allele is common in African populations [40].”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Could not verifycites [40] JA Tennessen, 2012, Evolution and functional impact of rare coding variation from deep sequencing of human exomes, Science sourceExperimental — accuracy not yet measured
Our copy of Tennessen et al. (2012) never mentions C1orf95: searches for 'C1orf95', for a variant common/high-frequency in African populations, and for the candidate-gene lists (Impact of natural selection on rare coding variation; Patterns of coding variation by gene and pathway) returned only genome-wide summaries, with named loci limited to HLA, DEFB108B, olfactory receptors and histone genes. The paper reports general population-frequency patterns — 86% of >500,000 SNVs rare (MAF <0.5%), 82% population-specific, and higher diversity in AAs (Abstract; Data generation and variant discovery) — but makes no locus-specific statement about a C1orf95 allele. Nothing in our copy contradicts the claim either, so it cannot be settled from this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“the case-control data have been carefully harmonized to minimize batch effects by using stringent quality control filters [7]”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Discussion
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Results section, “Harmonizing Calls of Genotype across Sequencing Platforms,” describes increasingly stringent filters used to make the case-control datasets more similar. The Discussion says the authors constructed additional filters to reduce differences in rare-variant distributions between sequencing centers, while cautioning that some heterogeneity could remain after filtering. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis.”
- Also stated in: § Power analysis by simulation · plain
“This comprehensive simulation showed TADA has superior power relative to the other two tests (Figure S3).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Power analysis by simulation · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“matching the expected with the observed value of , we estimate the the number of ASD risk genes is between 550 to 1000 (Figure 3B).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Genetic architecture of ASD
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
52 more claims
Create a free account to see all 110 claims and to verify the 23 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“TADA genes were defined as a set of 113 ASD genes that were associated with ASD at an FDR < 0.05.”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We applied a rare-variant transmission and de novo association (TADA) test33 to the combined data in this study to define a set of 125 ASD susceptibility (TADA genes) with FDR < 0.05”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, the discovery of less penetrant disorders can be empowered by analytical methodologies that integrate both DNMs and rare inherited variants, such as TADA34.”
From Evidence for 28 genetic disorders discovered by combining healthcare and research data (2020) · cites this paper as [34]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“We control for the multiple hypothesis testing using the Benjamini-Hochberg procedure [11].”
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 5×
“The missense labels are based on predictions from PolyPhen2.”
InfluentialGenomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162 · cited 1×
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] lq~1:02 (see Text S1).”
Self-citationVisscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.029 · Cited by 2,425 · cited 1×
“It has proven successful for identifying common variation affecting risk, after sufficient samples had been amassed to ensure variation having modest impact on risk could be detected [12].”
Tackling the widespread and critical impact of batch effects in high-throughput data
Leek, J. T., Scharpf, R. B., Bravo, H. C., Simcha, D., Langmead, B., Johnson, W. E., Geman, D., Baggerly, K., & Irizarry, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2825 · Cited by 2,196 · cited 1×
“Genotyping/sequencing errors can introduce biases in data analyses, especially those for family data [37,38] and for combining data across multiple heterogeneous studies [39].”
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations
O’Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., Levy, R., Ko, A., Lee, C., Smith, J. D., et al. (2012) · Nature · doi:10.1038/nature10989 · Cited by 2,165 · cited 7×
“Consider the de novo LoF mutations in N~932 families [1–4].”
InfluentialRate of de novo mutations and the importance of father’s age to disease risk
Kong, A., Frigge, M. L., Masson, G., Besenbacher, S., Sulem, P., Magnusson, G., Gudjonsson, S. A., Sigurdsson, A., Jonasdottir, A., Jonasdottir, A., et al. (2012) · Nature · doi:10.1038/nature11396 · Cited by 2,134 · cited 1×
“A recent study identified an additional de novo protein-changing mutation in CUL3 in ASD probands [27], replicating our finding here.”
De novo mutations revealed by whole-exome sequencing are strongly associated with autism
Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willsey, A. J., Ercan-Sencicek, A. G., DiLullo, N. M., Parikshak, N. N., Stein, J. L., et al. (2012) · Nature · doi:10.1038/nature10945 · Cited by 2,084 · cited 7×
“For each gene, the total rate of base pair substitutions was estimated using a probability model taking the gene length and base content into account [1].”
InfluentialSelf-citationFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013 · cited 1×
“Indeed virtually every discovery for ASD risk genes traces to rare and de novo variants [1–4,16–20].”
Patterns and rates of exonic de novo mutations in autism spectrum disorders
Neale, B. M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K. E., Sabo, A., Lin, C.-F., Stevens, C., Wang, L.-S., Makarov, V., et al. (2012) · Nature · doi:10.1038/nature11011 · Cited by 1,734 · cited 3×
“Based on computations of expected rates of de novo events as a function of a gene’s exonic length and base pair composition [2], a recent study [1] found that d§2 LoF events for Nv1000 is significant evidence to declare a gene as a risk gene (pv0:05, genomewide).”
Self-citation
Cited by
Synaptic, transcriptional and chromatin genes disrupted in autism
Study, T. D., De Rubeis, S., Autism, H. M. C. F., UK10K Consortium, The Autism Sequencing Consortium, He, X., Goldberg, A. P., Poultney, C. S., Samocha, K., Ercument Cicek, A., et al. (2014) · Nature · doi:10.1038/nature13772 · Cited by 2,746
Self-citationSatterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J.-Y., Peng, M., Collins, R., Grove, J., Klei, L., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.036 · Cited by 2,321
“Effect of Genetic Variants on ASD Risk Because protein-truncating variants (PTVs; nonsense, frameshift, and essential splice site variants) show a greater difference in burden between ASD cases and controls than missense variants, their average effect on liability must be larger (He et al., 2013).”
BackgroundMethodInfluentialSelf-citationLord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Self-citationInsights into autism spectrum disorder genomic architecture and biology from 71 risk loci
Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., Samocha, K. E., Cicek, A. E., Murtha, M. T., Bal, V. H., Bishop, S. L., Dong, S., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.016 · Cited by 1,430
“Second, many large CNVs contain sufficient numbers of genes that numerous ASD risk genes would be expected based solely on the fact that 800 genes are likely contributing to ASD risk (He et al., 2013; Sanders et al., 2012).”
BackgroundMethodInfluentialSelf-citationRare-Variant Association Analysis: Study Designs and Statistical Tests
Lee, S., Abecasis, G. R., Boehnke, M., & Lin, X. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.06.009 · Cited by 1,042
“131 In addition to the frequentist approaches we have primarily covered in this paper, Bayesian methods can provide an alternative framework for evaluating rare-variant association.”
Method
Metadata
- Authors
- He, X., Sanders, S. J., Liu, L., De Rubeis, S., Lim, E. T., Sutcliffe, J. S., Schellenberg, G. D., Gibbs, R. A., Daly, M. J., Buxbaum, J. D., State, M. W., Devlin, B., & Roeder, K.
- Affiliations
- Carnegie Mellon University (US)
- Yale University (US)
- Broad Institute (US)
- Vanderbilt University (US)
- University of Pennsylvania (US)
- Baylor College of Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Pittsburgh (US)
- Corresponding author
- Roeder, Kathryn
- ORCID
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-15
- Volume
- 9
- Issue
- 8
- Pages
- e1003671
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC3744441
- OpenAlex
- W2125226755
- Semantic Scholar
- 041f0c3d75072dec83d95d6bbf32c4757308d641
- Cited by
- 304
- References
- 42
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 29 · 2023: 18 · 2022: 23 · 2021: 31 · 2020: 25 · 2019: 24 · 2018: 26 · 2017: 23 · 2016: 27 · 2015: 21 · 2014: 15 · 2013: 1
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- Autism Speaks
- Simons Foundation
- Simons Foundation Autism Research Initiative
- National Institutes of Health (MH057881)
- National Institute of Mental Health (U01MH100209, R01MH061009, R01MH089025, U01MH100229, MH089004, MH089025, R01MH089175, R01MH089004, R37MH057881, R01MH089208, U01MH100239, R01MH057881, MH089482, MH057881, R01MH089482, MH061009, U01MH100233)
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- de novo mutations, autism spectrum disorder, TADA, Bayesian hierarchical model, penetrance, allele frequency, exome sequencing
- MeSH terms
- Bayes Theorem, Child Development Disorders, Pervasive, Humans, Models, Theoretical, Mutation, Risk Factors, Genetic Variation, Likelihood Functions, Case-Control Studies, Sequence Analysis, DNA, Genetic Predisposition to Disease, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes. https://app.cochat.ai/papers/10.1371/journal.pgen.1003671
- The paper
- He, X., Sanders, S. J., Liu, L., De Rubeis, S., Lim, E. T., Sutcliffe, J. S., Schellenberg, G. D., Gibbs, R. A., Daly, M. J., Buxbaum, J. D., State, M. W., Devlin, B., & Roeder, K. (2013). Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1003671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.